Tracking Blood Changes in Early Plasma Cell Disease Over Three Years

Plain-English translation of NCT02726750 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated July 2026 · How we translate trials

What is this trial?

This research study is following patients who have been diagnosed with monoclonal gammopathy of undetermined significance or smoldering multiple myeloma — two early conditions that sometimes develop into full multiple myeloma. Researchers want to understand which patients are most likely to progress to active myeloma, and they're doing this by collecting blood samples regularly and looking at genetic markers that might predict this progression.

Right now, doctors can't easily predict which patients with early plasma cell disease will eventually develop multiple myeloma and which won't. By studying this carefully over time, researchers hope to identify warning signs that could help doctors catch the disease earlier or monitor patients more effectively.

Do you qualify?

You likely qualify if…

you have been diagnosed with monoclonal gammopathy of undetermined significance (MGUS) with specific lab findings showing low levels of monoclonal protein and fewer than 10% abnormal plasma cells in your bone marrow
you have been diagnosed with smoldering multiple myeloma with specific lab findings showing higher levels of monoclonal protein or abnormal plasma cells between 10-60% in your bone marrow
you do not currently have features of active multiple myeloma such as high calcium levels, kidney problems, anemia, or bone lesions
you have not received chemotherapy or other systemic treatments for your plasma cell disease

You likely don't qualify if…

you have signs of active multiple myeloma including high calcium levels, kidney damage, low blood counts, bone lesions, or significant light chain abnormalities
you have more than 60% abnormal plasma cells in your bone marrow or more than one focal lesion on MRI
you have received prior chemotherapy or investigational treatment for your plasma cell disease
you have an active infection, uncontrolled illness, or psychiatric condition that would make it difficult to participate in the study

What participation looks like

You would visit the clinic every 6 months for 3 years to have blood samples drawn and your disease monitored. Your doctor may also order imaging tests like x-rays, CT scans, PET scans, or MRI scans, and occasionally a bone marrow biopsy, based on what they think is clinically necessary. After the first 3 years, you would continue to be followed up every 6-12 months to see if your condition changes.

AI-generated summary from trial data · Jul 6, 2026 · Not medical advice

Trial locations(1 site)

United States

M D Anderson Cancer Center, Houston, Texas